Revenue Breakdown
Composition ()
No data
Revenue Streams
Gilead Sciences Inc (GILD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Biktarvy, accounting for 49.8% of total sales, equivalent to $3.53B. Other significant revenue streams include Descovy and Yescarta. Understanding this composition is critical for investors evaluating how GILD navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Gilead Sciences Inc maintains a gross margin of 79.80%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 45.18%, while the net margin is 39.28%. These profitability ratios, combined with a Return on Equity (ROE) of 40.62%, provide a clear picture of how effectively GILD converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, GILD competes directly with industry leaders such as AMGN and ARGX. With a market capitalization of $174.49B, it holds a significant position in the sector. When comparing efficiency, GILD's gross margin of 79.80% stands against AMGN's 71.29% and ARGX's 90.29%. Such benchmarking helps identify whether Gilead Sciences Inc is trading at a premium or discount relative to its financial performance.
